株式会社renue
AI導入・DXの悩みをプロに相談してみませんか？
AIやDXに関する悩みがありましたら、お気軽にrenueの無料相談をご利用ください。 renueのAI支援実績、コンサルティングの方針や進め方をご紹介します。
FDA Compounding Pharmacy 503A/503B は、米国 Drug Quality and Security Act（DQSA、2013 年）で整備された医薬品調剤制度で、FD&C Act Section 503A（State-licensed Pharmacy 個別処方調剤）と Section 503B（Outsourcing Facility 大量調剤）の 2 経路を規定。2012 年 New England Compounding Center（NECC）真菌汚染事件（Fungal Meningitis・死亡 76 名）を契機に連邦監督強化。FDA 公式 GLP-1 Compounders Policy Clarification（FDA Clarifies Policies Compounders GLP-1）・Foley & Lardner 分析 2026-04（Foley FDA Compounders GLP-1 2026-04）・Skadden 2024-12 分析（Skadden GLP-1 Compounding Post-Shortage）で運用・最近動向。503A 特徴：State Licensed Pharmacy・個別 Valid Prescription 必須・USP<795>/<797> 適合・FDA Direct Registration 不要・通常州当局 Inspection。503B 特徴：FDA Registered Outsourcing Facility・Bulk Compounding（処方不要）・Full cGMP（21 CFR 211）・FDA Direct Inspection・Adverse Event Reporting。共通：FDA-approved Drug の Essentially a Copy 調剤禁止（Shortage List 時除外）。GLP-1 Shortage 事例：Semaglutide 2022-03・Tirzepatide 2022-12 FDA Shortage List 追加、Compounded GLP-1 製造急増、Tirzepatide 2024-12-19 Shortage Resolved・Semaglutide 2025-02-21 Shortage Resolved、503A Tirzepatide 終了 2025-02-18・Semaglutide 2025-04-22、503B Tirzepatide 2025-03-19・Semaglutide 2025-05-22 終了。FDA 2026-04-01 政策明確化で 503A が月 4 処方以下の Essentially a Copy 調剤は FDA Enforcement 対象外。Outsourcing Facilities Association は Semaglutide Shortage Resolution を Reckless/Arbitrary と訴訟。Adverse Event 報告（GI Side Effect・Overdose・Injection Site Reaction・Hospitalization）増加。本記事では、FDA Compounding Pharmacy の AI 支援を、503A/503B 区分・Essentially a Copy 判定・Shortage Policy・cGMP 適合の観点で玄人目線で詳述する。
DQSA 2013 の 503A と 503B
| 区分 | 503A | 503B |
|---|---|---|
| Licensing | State Licensed Pharmacy | FDA Registered Outsourcing Facility |
| Prescription | 個別 Valid 必須 | 不要（Bulk） |
| GMP | USP<795>・<797> | cGMP（21 CFR 211） |
| Inspection | 州当局 | FDA Direct |
| Adverse Event Reporting | 任意 | FDA へ義務 |
| Federal Registration | 不要 | 必須 |
| Essentially Copy Rule | 禁止（月 4 Rx 以下除外） | 禁止 |
| Shortage List 時 | Copy 調剤可能 | Copy 調剤可能 |
GLP-1 Shortage Timeline
- 2022-03 Semaglutide Shortage List 追加
- 2022-12 Tirzepatide Shortage List 追加
- 2023-2024 Compounded GLP-1 大量供給
- 2024-12-19 Tirzepatide Shortage Resolved
- 2025-02-18 503A Tirzepatide 終了
- 2025-02-21 Semaglutide Shortage Resolved
- 2025-03-19 503B Tirzepatide 終了
- 2025-04-22 503A Semaglutide 終了
- 2025-05-22 503B Semaglutide 終了
- 2026-04-01 FDA 政策明確化（503A 月 4 Rx 以下例外）
DQSA 創設の背景（NECC 事件）
| 事象 | 内容 |
|---|---|
| 2012-09 NECC Contamination | New England Compounding Center 真菌汚染 |
| 被害 | Fungal Meningitis 発症 753 名・死亡 76 名 |
| 原因 | Methylprednisolone Acetate Injection 汚染 |
| 規制 Gap | 連邦監督不在・州個別 Oversight |
| 議会対応 | 2013 年 DQSA 立法 |
| 新制度 | 503B Outsourcing Facility 創設 |
| FDA Authority | Direct Registration・Inspection 付与 |
| Track & Trace | Title II で Supply Chain 監視 |
Essentially a Copy Rule
- FDA-approved Drug と Identical or Nearly Identical 調剤禁止
- 例外：Shortage List 時・Clinical Difference 証明
- 503A 例外：Regularly/Inordinate Amount 調剤禁止
- 2026-04 FDA 明確化：月 4 Rx 以下で Enforcement 対象外（503A）
- 503B：Shortage List 時のみ Copy 可能
- Clinical Difference 例：Preservative-free・Allergen-free
- Bulk Drug Substance Categories 制限
- Bulk Drug Substance List 運用
AI 支援の 8 領域
1. 503A vs 503B 判定
Compounder Scale・Prescription Pattern から最適 Category を AI で判定。Registration 戦略。
2. Essentially Copy 判定
FDA-approved Drug と Compounded Product の類似性を AI で評価。Clinical Difference Justification。
3. Shortage List 追跡
FDA Shortage List 動的変化を AI で監視。Compounding Authorization 判定。
4. cGMP 適合（503B）
21 CFR 211 Full cGMP 対応を AI で支援。FDA Inspection Readiness。
5. USP<795>/<797>/<800> 運用（503A）
Non-sterile<795>・Sterile<797>・Hazardous<800> Compounding Standard を AI で統合。
6. Adverse Event Reporting
503B FDA AE Report を AI で自動化。FAERS 連携。
7. Bulk Drug Substance List
503A Category 1/2/3 Bulk Drug Substance List を AI で Tracking。
8. GLP-1 Post-Shortage 戦略
2025-2026 GLP-1 終了後の Compounding 戦略を AI で評価。月 4 Rx Enforcement 境界。
AI パイプライン
- Step 1: Compounder Type Decision
- Step 2: 503A or 503B 登録
- Step 3: Facility 設計（cGMP or USP<797>）
- Step 4: Drug Portfolio 選定
- Step 5: Essentially Copy Check
- Step 6: Shortage Status 確認
- Step 7: Compounding 実施
- Step 8: QC + Stability
- Step 9: FDA Inspection（503B）
- Step 10: Post-market AE Reporting
FDA Compounding Policy 2026-04 明確化
- 2026-04-01 FDA 声明（April Fool's Day ではない）
- 503A 月 4 Rx 以下の Essentially Copy は Enforcement 対象外
- Individual Patient Need 証明可能
- Clinical Difference Documentation
- Regularly/Inordinate 閾値明確化
- 503B 厳格維持
- Bulk Drug Substance Category 運用継続
- Telehealth Compounding 監視強化
地域別 Compounding 規制
| 地域 | 制度 |
|---|---|
| FDA | DQSA 2013 + 503A/503B + FDA Shortage Authority |
| EMA | EU Good Practice for Preparation of Medicinal Products in Hospital Pharmacies |
| PMDA | 薬機法 特定用途医薬品・院内調製 |
| NMPA | 医院制剂・调配 |
| MHRA | Specials Licence・Section 10 |
| Health Canada | National Association of Pharmacy Regulatory Authorities（NAPRA） |
| Australia TGA | Extemporaneous Compounding |
失敗パターンと回避策
落とし穴1：503A/503B 区分誤認
Bulk Compounding without Prescription を 503A で実施し違反。AI で事前判定。
落とし穴2：Essentially Copy 超過
Shortage 終了後も Copy 継続で FDA Action。AI で Shortage Monitoring。
落とし穴3：cGMP Non-compliance（503B）
21 CFR 211 Full cGMP 未達で FDA 483。AI で Readiness Check。
落とし穴4：USP 失注（503A）
<795>/<797>/<800> 実装不全で州当局指摘。AI で Audit Trail。
落とし穴5：月 4 Rx 閾値誤認
2026-04 FDA 明確化を誤適用で Enforcement Risk。AI で Rx Counting。
KPI 設計の観点
- 503A/503B 区分適合
- cGMP Inspection Pass Rate（503B）
- USP 実装（503A）
- Essentially Copy Compliance
- Shortage Monitoring 即応性
- Adverse Event Reporting（503B）
- Bulk Drug Substance List 準拠
まとめ：FDA Compounding AI 支援の設計指針
- DQSA 2013 + FD&C Act Section 503A/503B
- 2012 NECC 事件（死亡 76 名）契機の連邦規制整備
- 503A State Pharmacy（Rx 必須・USP）vs 503B Outsourcing（Bulk・cGMP）
- GLP-1 Shortage Timeline（2022-03 開始・2025-05 完全終了）
- 2026-04-01 FDA 明確化（503A 月 4 Rx 以下例外）
- Essentially Copy Rule 厳格（Shortage 例外）
- Telehealth Compounding 監視強化
- Outsourcing Facilities Association 訴訟継続
- USP<795>/<797>/<800> + 21 CFR 211
- AI は Type・Copy・Shortage・cGMP・USP・AE・Bulk List・Post-GLP-1、最終判断は Pharmacist・Regulatory・Legal・QA
FDA Compounding Pharmacy 503A/503B は DQSA 2013 + 2012 NECC 事件契機の連邦規制で、503A（State Pharmacy・Rx 必須）と 503B（Outsourcing Facility・cGMP）の 2 経路。GLP-1 Shortage（Semaglutide 2022-03・Tirzepatide 2022-12）→ Resolved（2024-12・2025-02）→ Compounding 終了（2025-04・2025-05）の Timeline、2026-04-01 FDA 政策明確化で 503A 月 4 Rx 以下例外。AI による 503A/503B 判定・Essentially Copy Check・Shortage Monitoring・cGMP 適合・USP 運用・AE Reporting で Compounding 戦略効率化。判断の人間主導と反復的 Copy 判定・Shortage 追跡の AI 自動化が、グローバル医薬品供給・個別化治療の競争力を決定づける。
renue独自視点：FDA Compounding 503A/503B AI支援の3つの落とし穴
renue社はPV/GMP/品質/臨床試験/AI創薬/BMV/Drug Shortage/RWD/IDMP/PPS/DHCPL/SaMD/DDI/Controlled Substance/AMR/SSDC/PGx/ERA/Packaging/BE/WHO PQ/Project Orbis/QT-QTc/RTOR/EU QP/PREA/PRV/S1B(R1)/BTD/Fast Track/EUA/S9/M12/CGT/S6(R1)/IRA/S5(R3)/340B/ACCESS/S7A-S7B/PMDA Reliance/PMR-PMC/Q5D/OTC Monograph/PDG Pharmacopoeia領域で90本（A088-A177）のシリーズを蓄積し、Compounding 503A/503BがA139 Drug Shortage（GLP-1事例）・A137 Generic/ANDA（Branded薬Compounding Copy禁止）・A177 PDG Pharmacopoeia（USP<795>/<797>/<800>整合）・A146 Controlled Substance Compounding・A151 ISO 15378 Container Closure・A110 ICH Annex 1 CCS（Sterile Compounding）・A112 PV Signal Compounding特有・A143 DHCPL Compounding Communication・A176 OTC Monograph対比・A147 AMR Compounding・A149 PGx個別化Compounding・A168 IRA Medicare Compounding除外・A170 340B Specialty Compoundingと密接交差する「Individualized Medicine × Federal-State Regulatory Dual Framework」の核心と認識している。本稿ではCompounding AI支援で汎用LLMが届かない3落とし穴を、一次資料（FDA 503B Registered Outsourcing Facilities・CRS R45069 Drug Compounding・FDA 503B Bulk Drug Substances・FDA Law Blog 2025-10 House Bill 503A MOU廃止）を参照し整理する。
落とし穴① 503A vs 503B Classification・Patient-specific Prescription要件・MOU/5% Interstate Limit・Essentially Copy判定の「Federal-State Dual Framework精度」
503A（State-regulated Traditional Compounding Pharmacy・Rx必須・FDCA 505/Approved Drug Exempt但しUSP<795>/<797>/<800>必須）vs 503B（Outsourcing Facility・Rx不要・cGMP 21 CFR 211必須・FDA登録）の2経路体系：①503A（Patient-specific Rx・Bulk Drug Substance Listまたは USP/NF Monograph・Essentially Copy禁止・Interstate 5%制限MOU未締結State）、②503B（Bulk Drug Substance 503B Clinical Need List収載or Drug Shortage List・CGMP Full Compliance・FDA Inspection年次・Adverse Event Reporting FDA直接・Biennial Product Reporting・Labeling Requirements）、③2025-10 House Bill 503A MOU廃止提案（Interstate Limit 5%撤廃議論）、④2026-04-01 FDA政策明確化（503A Limited Distribution Allowance月4Rx以下例外）、⑤DQSA Drug Quality and Security Act 2013-11-27（NECC 2012 Fungal Meningitis Outbreak 751例64死亡契機）、⑥Compounding Quality Act (Title I of DQSA)、⑦Drug Supply Chain Security Act (Title II of DQSA)（CRS R45069）。汎用LLMに「503A vs 503B戦略を」と頼むと基本は出るが、①State Board of Pharmacy License（50 States差）、②MOU Memorandum of Understanding締結State（2015 Draft MOU未Final化・2025-10 House Bill廃止提案）、③Interstate 5% Compliance Audit（Distribution vs Dispense区別・Complex算定）、④Essentially Copy Rule（Commercially Available Drug複製禁止・Shortage時例外・Different Strength/Different Form/Different Route例外）、⑤Essentially Copy判定境界（Concentration変更/Salt変更/Ester変更/Enantiomer変更/Dosage Form変更）、⑥Bulk Drug Substance 503A Category 1（Under Evaluation）vs Category 2（Non-USP-listed）vs 503A-IBULKS Bulks List、⑦503B Bulks List（Clinical Need判定）、⑧USP<795> Non-sterile Compounding、⑨USP<797> Sterile Compounding（BUD Beyond-Use Date・2023-11-01施行最新版・ISO Class 5 PEC Primary Engineering Control・PPE Personal Protective Equipment）、⑩USP<800> Hazardous Drug Compounding（NIOSH List連動）、⑪21 CFR 211 CGMP Full Compliance（503Bのみ）、⑫cGMP Compounding Specific Guidance for 503B Facilities、⑬GLP-1 Compounding事例（Semaglutide Ozempic/Wegovy/Rybelsus 2022-03 Shortage List→2025-02 Resolved→2026-04-01 Transition Period終了・Tirzepatide Mounjaro/Zepbound 2022-12 Shortage→2024-12 Resolved→2025-04-01 Transition終了）、⑭Compounding Pharmacy規模推計・Market Size（$15B 2024）、⑮Telehealth Compounding（Direct-to-Consumer Hims/Noom/Ro/Eden Weightloss Platform）、⑯Patient Safety Records (FDA Pharmaceutical Adverse Events Reporting System FAERS Compounding Signal)、⑰FDA 503B MOU訴訟（Outsourcing Facilities Association OFA vs FDA継続）、⑱A139 Drug Shortage List連動（Compounding Trigger）、⑲A137 Generic/ANDA参入後Compounding状況変化、⑳A146 Controlled Substance Compounding（Schedule II-V DEA Additional Compliance・Pseudoephedrine・Testosterone・Ketamine事例）、㉑A149 PGx個別化Compounding（Genotype-specific Dose・Pediatric Rare）、㉒A158 PREA Pediatric Compounding、㉓A176 OTC Monograph vs Compounding境界、㉔A147 AMR抗菌薬Compounding（Streamlined Rx vs Compounded Antibiotic）、㉕A150 ERA Hazardous Drug Compounding環境影響（USP<800>連動）、㉖A151 ISO 15378 Container Closure Compounded Productsなど LLM単独で体系化できない。対策は、①503A/503B Classification Agent（Patient-specific Rx + Bulk Drug Substance Status + cGMP Compliance Capability + Interstate Distribution Volume複合Score）、②Essentially Copy Rule Validator（Concentration/Salt/Ester/Enantiomer/Dosage Form変更判定）、③MOU State Tracker + Interstate 5% Audit、④Bulk Drug Substance List Monitor（503A + 503B Clinical Need List）、⑤USP<795>/<797>/<800> Compliance Checker、⑥GLP-1 Compounding Timeline Tracker、⑦Telehealth Compounding Monitor、⑧A139 Drug Shortage × Compounding Trigger、⑨A137 Generic Entry × Compounding、⑩A146 Controlled Substance Compliance、⑪A149 PGx Individualization、⑫A158 Pediatric Compounding、⑬A176 OTC Monograph vs Compounding、⑭A147 AMR Compounded Antibiotic、⑮A150 ERA Hazardous Drug、⑯5者合議（Regulatory Affairs・Pharmacist Leader・Legal・QA・Commercial）＋Compounding Pharmacy KOL＋Legal Counsel。
落とし穴② cGMP Compliance・FDA Inspection・USP<795>/<797>/<800>・Biennial Product Reporting・Adverse Event Reporting・Telehealth Compoundingの「Quality×Safety監視精度」
503B特有のCGMP Full Compliance：①21 CFR 211 Full CGMP・USP Integration・CGMP for 503B Facilities Guidance・Sterility Testing USP<71>（A177 PDG調和）・Endotoxin Testing USP<85> rFC/LAL・Stability USP<1150>/<1191>・Environmental Monitoring Class 5 PEC・Particulate Monitoring USP<788>/<1788>・Bioburden Testing USP<61>・Incoming Raw Material Test・Finished Product Release Test・BUD Beyond-Use Date Stability-based、②FDA Inspection Frequency（通常Biennial・Priority Risk-based）、③503B Warning Letters 2024-2025事例分析、④Biennial Product Reporting（毎年7月30日・11月30日 二回）、⑤Adverse Event Reporting FDA Form 3500A直接、⑥Labeling Requirements（Drug Name・Ingredient Concentration・Lot Number・Expiry Date・Outsourcing Facility Name/Address・「Compounded by ... in accordance with the ... of the FDCA」Statement・「Not for Resale」Labeling）、⑦21 CFR 207 Registration・Listing、⑧503B National Drug Code（NDC）規則、⑨503B Biennial Product Registration、⑩Telehealth Compounding監視（2024-2025 FDA・FTC Investigations増加・Hims/Hers/Ro/Noom・GLP-1 Direct-to-Consumer）、⑪Social Media Marketing Compliance（Opportunistic Claims・Research Chemical代替販売）、⑫Clinical Pharmacology Responsibility Practitioner（Compounding Practice vs Manufacturing区別）、⑬Pharmacist Supervision要件、⑭A110 ICH Annex 1 CCS Sterile Compounding 2023-08運用整合、⑮A102 EBR Electronic Batch Record・A103 ICH Q9(R1) QRM運用、⑯A138 ICH M10 BMV Analytical Method Validation、⑰A141 IDMP Compounded Product Master Data、⑱A175 ICH Q5D Cell Substrate Compounding（Autologous CAR-T Compounding特殊）、⑲A112 PV Signal Compounding Adverse Event、⑳A143 DHCPL Compounding Safety Communication、㉑A135 CCDS Compounded Product Label、㉒A143 Risk Mitigation Strategy（Compounding REMS風）、㉓Essential Outbreak事例学習（NECC 2012・Fungal Meningitis・Cataract Eye Drop Contamination 2023-01 Artificial Tears Pseudomonas aeruginosa・ Meta-cresol Preservative混入）、㉔Digital cGMP Integration（A132 AI Credibility Framework・A144 SaMD連動）、㉕A147 AMR抗菌薬Compounding Stewardship、㉖A146 Controlled Substance Compounding DEA Joint Audit、㉗A151 ISO 15378 Primary Packaging Compounded Specific、㉘A110 Annex 1 CCS Contamination Control、㉙Pharmacy Benefit Manager PBM × Compounding、㉚Long-term Care LTC Facility Compounding、㉛Home Infusion Compounding、㉜Oncology Compounding（A146 Cytotoxic）、㉝Pediatric Compounding（A158 PREA・A169 DART連動）、㉞Veterinary Compounding FDA 2025-04 New Draft Guidance、㉟Medicare Part B Compounding Reimbursement（Hospital Outpatient・A168 IRA連動）、㊱Medicaid Rebate Drug Program 503B Compound、㊲State Medical Board Pharmacy Board 協調、㊳U.S. State Pharmacy Regulation比較（California・Texas・New York・Florida厳格州 vs Permissive州）、㊴Compounding Litigation増加（Product Liability・Mass Tort・Multi-district Litigation）をLLM単独で体系化できない。対策は、①503B cGMP Readiness Agent（21 CFR 211 + USP<795>/<797>/<800> + FDA Inspection準備Score）、②FDA Warning Letter Risk Monitor、③Biennial Product Report Auto-generator、④Adverse Event Reporting Agent（FDA Form 3500A Auto-fill）、⑤Labeling Compliance Checker、⑥Telehealth Compounding Compliance Auditor、⑦Social Media Marketing Claims Validator、⑧Sterile Environmental Monitoring Dashboard（Particulate USP<788>/<1788>・Bioburden USP<61>・Endotoxin USP<85>）、⑨A110 Annex 1 CCS × Compounding連動、⑩A102 EBR・A103 Q9(R1) QRM・A138 BMV・A141 IDMP・A175 Q5D連動、⑪A112/A143/A135 Post-approval連動、⑫Outbreak Learning Database（NECC 2012・2023 Artificial Tears等）、⑬A132 AI Credibility × Digital cGMP、⑭A147 AMR/A146 Controlled Substance/A151/A110/A158/A169特殊連動、⑮Veterinary Compounding 2025-04 Draft Guidance、⑯6者合議（Chief Pharmacist・QA Director・Regulatory Affairs・Commercial・Legal・Clinical）＋FDA Compounding Inspection OBKOL＋USP Compounding Expert＋State Board of Pharmacy Advisor。
落とし穴③ Drug Shortage連動Compounding・GLP-1 Transition・Bulk Substance List Amendment・State-Federal Harmonization・Peptide Therapeuticsの「Market Access Complexity & Policy Uncertainty管理」
Compoundingの最大Wild CardはDrug Shortage連動の動的市場・GLP-1 Transition・Bulk Substance List Politics・Peptide Therapeutics Legal Gray Zone（FDA 503B Bulk Drug Substances）。汎用LLMに「Compounding Market戦略を」と頼むと一般論は出るが、①GLP-1 Compounding Timeline（Semaglutide 2022-03-31 FDA Shortage→2025-02 Resolved Announcement→2025-02-20 503A Distribution停止→2025-05-22 503B停止、Tirzepatide 2022-12 Shortage→2024-12-19 Resolved→2025-03-19 503A停止→2025-05-02 503B停止・訴訟で一部継続）、②OFA Outsourcing Facilities Association v. FDA訴訟（2024-2025 Tirzepatide Shortage判定訴訟・State Board 独自 Shortage判定）、③2025-10 House Bill「Compounding During Drug Shortages Expansion + Bulk Substance USP/NF Monograph Definition明確化 + 503A MOU 廃止」提案、④Bulk Substance List Amendment Process（Stakeholder提案・Clinical Need判定・FDA決定・Federal Register公布・Public Comment 60日・Final Rule）、⑤Semaglutide/Tirzepatide Compounding $1B+市場のRevenue Shift、⑥Peptide Therapeutics Legal Gray Zone（BPC-157・TB-500・CJC-1295・Ipamorelin・Thymosin Alpha-1等 Research Chemical vs Compounding pharmacy vs Illicit Market）、⑦2025-04 FDA Peptide Compounding Policy明確化議論、⑧A137 Generic/ANDA参入でCompounding機会縮小（特にGeneric Low-cost化時）、⑨A139 Drug Shortage × Compounding Trigger（Shortage Continuous/Resolved判定争議）、⑩A146 Controlled Substance Compounding（Pseudoephedrine・Methylphenidate・Adderall・Oxycodone・Ketamine・Psilocybin Research）、⑪A147 AMR抗菌薬Compounding（Vancomycin・Meropenem Shortage連動）、⑫A149 PGx Individualized Dose Compounding（CYP2D6 Poor Metabolizer Dextromethorphan・CYP2C19 PPI個別化）、⑬A158 PREA Pediatric Compounding（Liquid Formulation Extemporaneous Compounding・Taste-masking）、⑭Oncology Cytotoxic Compounding（A164 ICH S9連動・USP<800> Hazardous）、⑮Home Infusion Compounding・Long-term Care Compounding、⑯Hospital Pharmacy In-house Compounding（A173 PMDA院内製剤比較・Japan 医療機関による製剤）、⑰Telehealth Compounding Platform規制（Hims/Hers/Ro/Noom GLP-1・Testosterone・Finasteride・Tretinoin・Bupropion・Sildenafil/Tadalafil Erectile Dysfunction等）、⑱Direct-to-Consumer Marketing Compliance（FDA/FTC Joint Investigations 2024-2025）、⑲FDA Risk-based Enforcement Priority（High-risk Sterile vs Low-risk Non-sterile）、⑳A170 340B Specialty Pharmacy × Compounding、㉑A168 IRA Medicare Selected Drug × Compounding（Medicare Part Bに影響）、㉒Medicaid Rebate × Compounding、㉓Private Insurance Payer Coverage Compounded Drug、㉔ PBM Formulary Compounded Inclusion・Exclusion、㉕Compounding Pharmacy Marketing State Advertising Rules、㉖Compounding Pharmacy Outbreak Historical Timeline（Fatal Events・Recall Events）、㉗HHS Sections 201/503A/503B FDCA改正議論継続、㉘Multi-state License Compliance（Compounding Pharmacy 50 State License Navigation）、㉙ACA Affordable Care Act × Compounding、㉚ICD-10 Code Compounding Billing、㉛Compounding Pharmacy Insurance Liability、㉜FDA Compliance Program 7356.002 Compounding Inspection、㉝A143 DHCPL Compounding Risk Communication、㉞A135 CCDS Compounded Product Label、㉟Post-approval Commitments PMC × Compounding（Generic Market Entry Commitment延期時Compounding継続）、㊱VIP Compounding Veterinary Compounding 2025-04 Draft Guidance、㊲Animal Feed Additive Compounding、㊳Essential Medicine LMIC Compounding (A153連動・WHO Essential Medicines List)、㊴US Armed Forces Compounding・VA Veterans Affairs Compounding、㊵Indian Health Service IHS Compounding、㊶Research Pharmacy Compounding（Clinical Trial 臨床試験Compounding A148 ICH E19 SSDC連動）、㊷A166 CGT Designation × Compounding境界、㊸A163 EUA Emergency Compounding（COVID-19 Pandemic 2020-2023 Hand Sanitizer Compounding等）、㊹AI-based Compounding Decision Support（A132 AI Credibility Framework・A144 SaMD PCCP連動）、㊺Global Compounding Comparison（Japan 院内製剤・EU Extemporaneous Compounding・UK Pharmaceutical Compounding・Canada Compounding Regulations）をLLM単独で体系化できない。対策は、①GLP-1 Compounding Transition Tracker（Semaglutide/Tirzepatide Timeline + OFA Litigation）、②Drug Shortage × Compounding Trigger Monitor、③Bulk Substance List Amendment Watcher、④Peptide Therapeutics Legal Gray Zone Navigator、⑤2025-10 House Bill 503A MOU廃止追跡、⑥State-Federal Harmonization Dashboard、⑦Telehealth Compounding Compliance Auditor、⑧A139 Drug Shortage × Compounding・A137 Generic Entry・A146 Controlled Substance・A147 AMR・A149 PGx・A158 Pediatric・A164 Oncology Cytotoxic連動、⑨A173 PMDA Japan 院内製剤比較、⑩A170 340B × Compounding・A168 IRA × Compounding・Medicare Part B影響、⑪HHS FDCA改正議論Tracker、⑫Multi-state License Compliance、⑬FDA Compliance Program 7356.002監視、⑭A143/A135 Post-approval連動、⑮A166 CGT × Compounding境界、⑯A163 EUA Emergency Compounding、⑰AI-based Decision Support（A132/A144）、⑱Global Compounding Comparison（Japan 院内製剤/EU/UK/Canada）、⑲Veterinary Compounding 2025-04 Draft Guidance、⑳LMIC Essential Medicine Compounding（A153連動）、㉑7者合議（Chief Pharmacist・Regulatory Affairs・Legal・Commercial・BD・Medical Affairs・Telehealth Compliance）＋Compounding Pharmacy KOL＋GLP-1 Market Analyst＋Peptide Therapeutics Legal Expert＋State Board of Pharmacy Consultant＋Insurance Reimbursement Specialist＋FDA Law Firm Strategic Counsel。renue社は「503A/503B Classification Agent＋503B cGMP Readiness Agent＋GLP-1 Compounding Transition Tracker」をProtocol主導で運用し、汎用LLMでは届かないFDA Compounding 503A/503B AI支援の「Federal-State Dual Framework精度・Quality×Safety監視精度・Market Access Complexity & Policy Uncertainty管理」3落とし穴を塞ぐ。
